Abasaglar ® (basal insulin glargine)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Abasaglar Summary of Product Characteristics (SmPC)

Abasaglar® (insulin glargine): Manufacturing

The manufacturing process for Abasaglar is proprietary information.

Detailed Information

Abasaglar is produced by recombinant DNA technology in Escherichia coli.1

Lantus is produced by recombinant DNA technology in Escherichia coli.2

The manufacturing process for Abasaglar and Lantus is proprietary to their respective company.


1. Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Lantus [summary of product characteristics]. Sanofi-Aventis Deutschland GmbH, Germany.


Abasaglar = Abasaglar® (insulin glargine) 100 units/mL

Lantus = Lantus® (insulin glargine) 100 units/mL

Date of Last Review: June 11, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request